Patient demographics
| Characteristic . | Recipient without CMV n = 137 . | Recipient with CMV n = 157 . |
|---|---|---|
| Donor CMV+, n (%) | 49 (36%) | 73 (46%) |
| Conditioning intensity, n (%) | ||
| Ablative | 44 (32%) | 63 (40%) |
| Nonmyeloablative | 40 (29%) | 46 (29%) |
| Reduced intensity | 53 (39%) | 48 (31%) |
| Disease histology, n (%) | ||
| ALL | 6 (4.4%) | 11 (7.0%) |
| AML | 39 (28%) | 44 (28%) |
| CLL | 5 (3.6%) | 5 (3.2%) |
| HL | 5 (3.6%) | 7 (4.5%) |
| MDS/MPN | 45 (33%) | 46 (29%) |
| MM | 4 (2.9%) | 5 (3.2%) |
| NHL | 26 (19%) | 32 (20%) |
| Non-malignant disorder | 6 (4.4%) | 7 (4.5%) |
| Other | 1 (0.7%) | 0 (0%) |
| Sex, female, n (%) | 44 (32%) | 63 (40%) |
| Age, median (IQR) | 64 (56, 69) | 62 (53, 69) |
| Conditioning regimen, n (%) | ||
| Busulfan based | 16 (12%) | 10 (6.4%) |
| Fludarabine/cyclophosphamide/TBI | 45 (33%) | 54 (34%) |
| Melphalan based | 76 (55%) | 93 (59%) |
| Graft source, n (%) | ||
| Bone marrow | 37 (27%) | 47 (30%) |
| Mobilized blood | 100 (73%) | 110 (70%) |
| Donor relatedness, n (%) | ||
| HLA-matched related | 11 (8.0%) | 17 (11%) |
| HLA-mismatched related | 50 (36%) | 87 (55%) |
| HLA-matched unrelated | 31 (23%) | 19 (12%) |
| HLA-mismatched unrelated | 44 (32%) | 34 (22%) |
| Characteristic . | Recipient without CMV n = 137 . | Recipient with CMV n = 157 . |
|---|---|---|
| Donor CMV+, n (%) | 49 (36%) | 73 (46%) |
| Conditioning intensity, n (%) | ||
| Ablative | 44 (32%) | 63 (40%) |
| Nonmyeloablative | 40 (29%) | 46 (29%) |
| Reduced intensity | 53 (39%) | 48 (31%) |
| Disease histology, n (%) | ||
| ALL | 6 (4.4%) | 11 (7.0%) |
| AML | 39 (28%) | 44 (28%) |
| CLL | 5 (3.6%) | 5 (3.2%) |
| HL | 5 (3.6%) | 7 (4.5%) |
| MDS/MPN | 45 (33%) | 46 (29%) |
| MM | 4 (2.9%) | 5 (3.2%) |
| NHL | 26 (19%) | 32 (20%) |
| Non-malignant disorder | 6 (4.4%) | 7 (4.5%) |
| Other | 1 (0.7%) | 0 (0%) |
| Sex, female, n (%) | 44 (32%) | 63 (40%) |
| Age, median (IQR) | 64 (56, 69) | 62 (53, 69) |
| Conditioning regimen, n (%) | ||
| Busulfan based | 16 (12%) | 10 (6.4%) |
| Fludarabine/cyclophosphamide/TBI | 45 (33%) | 54 (34%) |
| Melphalan based | 76 (55%) | 93 (59%) |
| Graft source, n (%) | ||
| Bone marrow | 37 (27%) | 47 (30%) |
| Mobilized blood | 100 (73%) | 110 (70%) |
| Donor relatedness, n (%) | ||
| HLA-matched related | 11 (8.0%) | 17 (11%) |
| HLA-mismatched related | 50 (36%) | 87 (55%) |
| HLA-matched unrelated | 31 (23%) | 19 (12%) |
| HLA-mismatched unrelated | 44 (32%) | 34 (22%) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; TBI, total body irradiation.